Souped-up CARs at ASH 2018

How modifications to CAR T and CAR NK cells stand to boost their function

Rather than searching for new antigens, makers of the latest generation of CAR therapies are focusing on the CARs themselves by designing more sophisticated methods of targeting multiple antigens, controlling cytotoxicity and enhancing tumor-homing.

BioCentury’s analysis of abstracts released ahead of this year’s American Society of Hematology (ASH) meeting finds 226 abstracts on CARs, about 40 of which describe new approaches for controlling CAR T cells or CAR NK cells in early development, from academic discovery to first-in-human trials.

A selection of the strategies is depicted below, with relevant abstract numbers shown for each (see “Figure: CAR Schematics”).

Figure: CAR

Read the full 987 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers